Summary
This study investigates the mechanistic pathways by which baicalin, a bioactive flavonoid derived from Scutellaria baicalensis, attenuates intestinal inflammation, with particular focus on its regulation of M1 macrophage polarisation and modulation of gut microbiota, specifically Lactobacillus amylovorus. Published in Advanced Science in 2025, the work likely employs murine colitis models and/or cell culture systems to demonstrate that baicalin's anti-inflammatory effects are mediated at least in part through the gut-immune axis. The findings contribute to a growing body of evidence linking dietary phytochemicals to immunomodulatory and microbiome-mediated mechanisms relevant to inflammatory bowel conditions.
UK applicability
This preclinical study was likely conducted in China and does not directly address UK clinical or dietary contexts; however, its findings on plant-derived compounds and gut-immune interactions are of broad relevance to UK research on functional foods, phytochemicals, and inflammatory bowel disease management.
Key measures
M1 macrophage polarisation markers (e.g. TNF-α, IL-6, IL-1β); gut microbiota composition (16S rRNA sequencing); intestinal barrier integrity indicators; Lactobacillus amylovorus abundance
Outcomes reported
The study examined how baicalin, a plant-derived flavonoid, alleviates intestinal inflammation by inhibiting M1 macrophage polarisation and promoting the abundance of Lactobacillus amylovorus in the gut. Outcomes likely included inflammatory cytokine profiles, macrophage phenotyping, and gut microbiota composition.
Topic tags
Dig deeper with Pulse AI.
Pulse AI has read the whole catalogue. Ask about this record, its theme, or how the findings apply to UK farming and policy — every answer cites the underlying studies.